Enanta Announces Data to be Presented on AbbVie’s MAVYRET™...
16 HCV abstracts to be presented including 12 data presentations on the safety and efficacy of MAVYRET MAVYRET is recommended in new AASLD guidelines as a first line treatment option for 8 weeks in...
View ArticleMerck Receives Approval of ZEPATIER™ (elbasvir/grazoprevir) in Canada for the...
(Source: Merck Canada Inc) 00f0678e-090a-4f9c-a736-8cbc159b1544.pdf News Release FOR IMMEDIATE RELEASE Media Contact: Annick Robinson (438) 837-2550 Investor Contact: Amy Klug (908) 740-1898 Merck...
View ArticleEnanta Announces New Data from AbbVie’s SURVEYOR-1 and SURVEYOR-2 Studies...
(Source: Enanta Pharmaceuticals Inc) 97-98 percent SVRachieved with eight weeks of ABT-493 and ABT-530 treatment ingenotypes 1, 2 or 3 HCV patients without cirrhosis in SURVEYOR 1 and 2 studies 100...
View ArticleU.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza...
(Source: Bristol-Myers Squibb Company) PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that Daklinza (daclatasvir, 60 mg), an NS5A replication complex...
View ArticleFDA approves Technivie for treatment of chronic hepatitis C genotype 4 (FDA -...
(Source: FDA - Food and Drug Administration) Release The U.S. Food and Drug Administration today approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for...
View ArticleEnanta Pharmaceuticals Announces Investigational Regimen Containing Enanta’s...
(Source: Enanta Pharmaceuticals Inc) Data from AbbVie’s SURVEYOR-I and SURVEYOR-II studies demonstrate high sustained virologic response rates at 12 weeks post-treatment (SVR 12 ) in non-cirrhotic...
View ArticleEight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic,...
(Source: AbbVie Inc) - 99 percent (n=105/106) of genotype 1 (GT1) chronic HCV-infected Japanese patients without cirrhosis achieved SVR[12] with 8 weeks of G/P - Japan has one of the highest rates of...
View ArticleAbbVie's HOLKIRA™ PAK Now Reimbursed in Quebec
HOLKIRA PAK is now listed in the drug formularies covered by Quebec's public prescription drug insurance program for patients with genotype 1 hepatitis C virus infection. In Phase 3 clinical trials,...
View ArticleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies...
(Source: AbbVie Inc) NORTH CHICAGO, Ill., Nov. 16, 2015/PRNewswire / -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced data from the SURVEYOR studies of its investigational...
View ArticleAbbVie Updates U.S. Labels for VIEKIRA PAK® and TECHNIVIE™ (AbbVie Inc)
(Source: AbbVie Inc) NORTH CHICAGO, Ill., Oct. 22, 2015/PRNewswire / -- In consultation with the U.S. Food and Drug Administration (FDA), the U.S. Product Inserts (USPI) for VIEKIRA PAK® (ombitasvir,...
View ArticleEnanta Pharmaceuticals Announces HCV Data Presentations at The International...
(Source: Enanta Pharmaceuticals Inc) New data to be presented on EDP-494, Enanta's pan-genotypic cyclophilin inhibitor for Hepatitis C virus New data to be presented on AbbVie's investigational,...
View ArticleAbbVie Updates U.S. Labels for VIEKIRA PAK® and TECHNIVIE(TM)
NORTH CHICAGO, Ill., Oct. 22, 2015 /PRNewswire/ -- In consultation with the U.S. Food and Drug Administration (FDA), the U.S. Product Inserts (USPI) for VIEKIRA PAK® (ombitasvir, paritaprevir, and...
View ArticleAbbVie Updates U.S. Labels for VIEKIRA PAK® and TECHNIVIE™
NORTH CHICAGO, Ill., Oct. 22, 2015 /PRNewswire/ -- In consultation with the U.S. Food and Drug Administration (FDA), the U.S. Product Inserts (USPI) for VIEKIRA PAK® (ombitasvir, paritaprevir, and...
View ArticleAbbVie's HOLKIRA™ PAK Now Reimbursed in Ontario
Common Drug Review grants positive recommendation for HOLKIRA PAK Ontario is the second province in Canada to reimburse HOLKIRA PAK In Phase 3 clinical trials, HOLKIRA PAK (with or without ribavirin)...
View ArticleOngoing Real World Study Reports High Sustained Viral Response Rates with...
(Source: AbbVie Inc) - Interim results from the independent AMBER study demonstrated 98 percent (n=39/40) SVR(12) rate in patients who completed a 12- or 24-week treatment regimen and 12 weeks...
View ArticleAbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C...
NORTH CHICAGO, Ill., June 24, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained...
View ArticleAbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C...
- 100 percent SVR(12) rate achieved with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) without ribavirin(1) NORTH CHICAGO, Ill., June 24, 2015 /PRNewswire/ --...
View ArticleAbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C...
(Source: AbbVie Inc) - 100 percent SVR(12) rate achieved with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) without ribavirin(1) NORTH CHICAGO, Ill. , June 24,...
View ArticleAbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with...
NORTH CHICAGO, Ill., Feb. 27, 2017 /PRNewswire/ -- AbbVie ABBV, +0.24% a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the...
View ArticleLupin Bolsters US Brands Portfolio with Methergine® Oral Tablets
MUMBAI, India and BALTIMORE, April 28, 2016 /PRNewswire/ -- The only FDA-approved oral uterotonic for the management of PPH, comes to market with a significant investment in professional medical...
View Article